Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю., Ермак Т.Н., Буравцова Е.В., Шахгильдян В.И., Козырина Н.В., Нарсия Р.С., Зимина В.Н., Покровская А.В., Конов Д.С., Конов В.В., Голиусова М.А., Ефремова О.С., Попова А.А. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией 2013 // Эпидемиология и инфекционные болезни. Актуальные вопросы.- 2013.- № 6, Приложение.- 1-32 с.
Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 7.0; October, 2013) // European AIDS Clinical Society (http://www.europeanaidsclinicalsociety.org).http://www.europeanaidsclinicalsociety.org)
Sulkowski M., Pol S., Mallolas J., Fainboim H., Cooper C., Slim J., Rivero A., Mak C., Thompson S., Howe A.Y., WenningL., Sklar P., Wahl J., Greaves W. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis С virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial // Lancet Infect. Dis.- 2013a.- Vol. 13 (7).- Р.597-605.
Sulkowski M.S., Sherman K.E., Dieterich D.T., Bsharat M., Mahnke L., Rockstroh J.K., Gharakhanian S., McCallister S., Henshaw J., Girard.P.M., Adiwijaya B., Garg V., Rubin R.A., Adda N., Soriano V. Combination therapy with telaprevir for chronic hepatitis С virus genotype 1 infection in patients with HIV: a randomized trial // Ann. Intern. Med.- 2013d; Vol. 159 (2). - Р 86-96.
Cotte L., Vincent C., Sogni P., Fournier I., Aumaitre H., Truchis P. De, Rosa I., Chevaliez S., Aboulker J.-P., Molina J.-M. Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH). 21st CROI; March 3-6, 2013; Boston, MA. Abstract 668.- URL: www.croi2014.org (дата обращения 16.04.2014 г.).www.croi2014.org
Poizot-Martin, E. Bellissant, P. Colson, Renault A., PirothL., Solas C., Bourliere M., Garraffo R., HalfonP., Molina J.-M. and the ANRS HC27 BOCEPREVIH Study Group Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial. 21st CROI; March 3-6, 2014; Boston, MA. Abstract 659LB.- URL: www.croi2014.org (дата обращения 16.04.2014 г.).www.croi2014.org
Jacobson I., Dore G.J., Foster G.R., Fried M.W., Radu M., Rafalskiy V.V., Moroz L., Craxi A., Peeters M., Lenz O., Ouwerkerk-Mahadevan S., Kalmeijer R., Beumont-MauvielM. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. EASL, 2013, The Netherlands, A. 1425.- URL:.http://www2.kenes.com/liver-congress/sci-entific/Documents/Abstract_book.pdf (дата обращения 16.04.2014 г.).http://www2.kenes.com/liver-congress/sci-entific/Documents/Abstract_book.pdf
Lawitz E., FornsX., Zeuzem S., Gane E., BronowickiJ.-P., Andreone P., HorbanA., Brown A., PeetersM., Lenz O., Ouwerkerk-Mahadevan S., Kalmeijer R., Beumont-Mauviel M. Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From Promise, a Phase III Trial. Digestive Disease Week. Orlando, 2013. Abstract 869b].- URL:. www.natap.org/2013/DDW/DDW_06.htm (дата обращения 16.04.2014 г.).
Manns M., Marcellin P., Poordad F.P., Stanislau E., de Araujo A., Buti M., Horsmans Y., Ewa Janczewska E.J., Villamil F., Peeters M., Lenz O., Ouwerkerk-Mahadevan S., Kalmeijer R., Beumont-Mauviel M. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. EASL, 2013, The Netherlands, A. 1413.- URL: http://www2.kenes.com/liver-congress/scientific/Documents/Abstract_book.pdf (дата обращения 16.04.2014 г.).http://www2.kenes.com/liver-congress/scientific/Documents/Abstract_book.pdf
Recommendations for Testing, Managing, and Treating Hepatitis C. Guidelines of AASLD and IDSA, January 29, 2014.- URL:www.hcvguide-lines.orgHCVguidelines.org (дата обращения 25.04.2014 г.).www.hcvguide-lines.orgHCVguidelines.org
Dieterich D., Rockstroh J.K., Orkin C, Gutierrez F., Klein M.B., Reynes J., Tambuyzer L.,. Peeters M, Jenkins A., Jessner W. Simeprevir (TMC435) plus pegifn/ribavirin in HCV genotype-1/HIV-1 coinfection (Study C212). 21st CROI; March 3-6, 2014; Boston, MA. Abstract 24. - URL: www.croi2014.org (дата обращения 25.04.2014 г.).www.croi2014.org
Kakuda T., Leopold L., Nijs S., Vandevoorde A., Crauwels H., Bertelsen K., Stevens M., Witek, J., van Delft Y., Tomaka, F., Hill A., Hoetelmans R. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial [Abstract O-18]. 13th International Workshop on Clinical Pharmacology of HIV Therapy. April 16-18, 2012; Barcelona, Spain.- URL: http://regist2.virology-education.com/abstractbook/2012_3.pdf (дата обращения 25.04.2014 г.).http://regist2.virology-education.com/abstractbook/2012_3.pdf
de Kanter C., Blonk M., Colbers A., Fillekes Q., Schouwenberg B., BurgerD. The influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir [Abstract 772LB]. 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2012; Seattle, WA.- URL: www.croi2012.org (дата обращения 25.04.2014 г.).www.croi2012.org
Garraffo R., Poizot-Martin I., PirothL., Teicher E., Pol S., Bellissant E., Bourliere M., Molina J.M. Pharmacokinetic (PK) interactions between Boceprevir (BOC) and Atazanavir/r (ATV/r) or Raltegravir (RAL) in HIV/HCV coinfected patients (pts). [Abstract O-15]. 14th International Workshop on Clinical Pharmacology on HIV Therapy. April 22-24, 2013; Amsterdam, the Netherlands.- URL: http://regist2.virology-educa-tion.com/abstractbook/2013_3.pdf (дата обращения 25.04.2014 г.).http://regist2.virology-educa-tion.com/abstractbook/2013_3.pdf
Hammond K.P., Wolfe P., Burton J.R., Predhomme J.A., Ellis C.M., Ray M.L. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers // J. Acquir. Immune. Defic. Syndr.-2013.- Vol. 62 (1).- Р 67 - 73.
Hulskotte E.G., FengH.P., Xuan F., van Zutven MGJA, OMara E., Galitz L. Pharmacokinetic interactions between the hepatitis С virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir // Clin. Infect. Dis.- 2013.- Vol. 56(5).- Р 718-726.
Ouwerkerk-Mahadevan S., Sekar V., PeetersM., Beumont-MauvielM. The pharmokinetic interactions of HCV protease inhibitor TMC435 with RPV, TDF, EFV, or RAL in health volunteers [Abstract 49]. 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5 - 8, 2012; Seattle, Washington.- URL: www.croi2012.org (дата обращения 20.04.2014 г.).www.croi2012.org
ВИЧ-инфекция и хронические гепатиты: Медицинский тематический архивм/ Под ред. Н.А.Белякова, А.Г.Рахмановой, В.В.Рассохина.- СПб.: Балтийский медицинский образовательный центр, 2014.- 272 с.
de Ledinghen V., Barreiro P., Foucher J., Labarga P., Castera L., Vispo M.E., Bernard P.H., Martin-Carbonero L., Neau D., Garcia-Gasco P., Merrouche W., Soriano V. Liver fibrosis on account of chronic hepatitis С is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy // J. Viral. Hepat.- 2008.- Vol. 15 (6).- Р 427-433.